Pyridone Drug Class List

Drugs in Drug Class: Pyridone

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	PIRFENIDONE	pirfenidone	TABLET;ORAL	212560-001	Apr 28, 2022	AB	RX	No	No
Micro Labs	PIRFENIDONE	pirfenidone	TABLET;ORAL	212680-001	May 18, 2022	AB	RX	No	No
Macleods Pharms Ltd	PIRFENIDONE	pirfenidone	CAPSULE;ORAL	212748-001	Dec 18, 2024	AB	RX	No	No
Apotex	PIRFENIDONE	pirfenidone	TABLET;ORAL	212709-002	May 31, 2023	AB	RX	No	No
Sandoz	PIRFENIDONE	pirfenidone	TABLET;ORAL	212560-002	Apr 28, 2022	AB	RX	No	No
Micro Labs	PIRFENIDONE	pirfenidone	TABLET;ORAL	212680-002	May 18, 2022	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in the Drug Class: Pyridone

Last updated: April 24, 2026

What counts as “pyridone” in this landscape?

“Pyridone” is a chemical class term used for lactam and lactam-like heterocycles that contain a pyridinone core (commonly 2-pyridone or 4-pyridone motifs). In practice, “pyridone” appears across multiple therapeutic areas through distinct drug substances (not one unified platform). The patent landscape therefore clusters by specific active ingredients that share the pyridone scaffold rather than by a single, class-wide monopoly pattern.

This analysis is structured around (1) market dynamics that typically drive pyridone adoption and (2) how patent protection is typically built for small-molecule heterocycles (composition, polymorphs/solvates, process, and method-of-use), using the most visible regulatory and patent hooks: FDA/EMA approvals, Orange Book listed patents, and EPO/USPTO filings. Market access effects then follow from exclusivity expiries, generic entry timing, and label fragmentation.

What market forces shape pyridone prescribing and procurement?

Market dynamics for pyridone-containing drugs are mostly driven by standard small-molecule factors: clinical differentiation, safety/tolerability, dosing convenience, payer coverage, and competitive switching at patent expiry.

Core demand drivers

• Linearity of substitution at generic entry: When pyridone drugs lose exclusivity, demand often shifts rapidly to lower-cost generics or authorized generics if the molecules are bioequivalent and formulation barriers are low (no durable polymorph or solvate lock-in).
• Formulation sensitivity: For many heterocycles, differences in crystallinity, polymorph, or solvate stability can drive litigation and delay generic launches. This directly affects the practical timeline of erosion.
• Label scope breadth: Drugs that hold broader labeled indications (or have multiple approved indications) often maintain longer economic value than single-indication products because biosimilar-style label matching does not apply; instead, generic competition starts only where exclusivity and patent barriers align.

Key competitive constraints

• Therapeutic overlap across classes: Pyridone scaffolds compete indirectly with other mechanisms in the same disease setting. Even with patent protection, payer pressure can redirect use if a competitor gains formulary position or shows superior outcomes.
• Patent “stacking” versus clean-sheet competition: The biggest determinant of post-expiry pricing survival is whether the originator stack includes defensible secondary patents that reach to launch timing.

Regulatory and exclusivity timing effects

In the US, patent and exclusivity timing frequently hinge on:

• FDA Orange Book patent listing for patents covering the drug product and use. (Orange Book is the practical map for generic challenge planning.) [1]
• Hatch-Waxman framework for ANDA litigation via Paragraph IV challenges, which commonly determines the actual date of generic entry. [2]

How does the patent landscape typically look for pyridone drugs?

Pyridone-containing drugs tend to show a repeatable protection architecture:

1) Composition-of-matter (primary patent)

• Covers the active ingredient and often includes salts or specific stereochemistry.
• Often determines the absolute floor for generic entry unless there are broad terminal disclaimers or early invalidation.

2) Drug product patents (formulation, polymorphs, solvates)

• Covers solid-state form control: polymorph, hydrate, solvate, particle size distribution, and controlled-release platforms.
• These patents are frequently the main source of “late” infringement hooks that can extend effective exclusivity.

3) Method-of-use and dosing regimen patents

• Covers specific indications, lines of therapy, or patient subsets.
• Often used to maintain market share by preserving label differentiation against “carve-out” label generic strategies (where permitted).

4) Process and intermediate patents

• Covers manufacturing routes that reduce impurity profiles or improve yield.
• Process patents matter when generic manufacturers rely on different routes, enabling infringement arguments without copying the same formulation.

5) Regulatory exclusivities layered onto patents

• Orphan Drug designation and exclusivity (if granted).
• Pediatric exclusivity and other statutory exclusivities that can extend exclusivity periods independent of patents.

What does the actionable patent “map” look like in practice?

For pyridone-class drugs, the actionable view for investors and generic challengers typically comes from:

• FDA Orange Book: lists patents by drug product and indicates whether patents are tied to composition and/or use [1]
• US litigations and PTAB outcomes for challenged patents (Paragraph IV related)
• EPO family coverage for patent term extension and enforcement geography

Orange Book is the operational pivot because ANDA applicants design challenges around it. [1]

What are the most common market outcomes at exclusivity cliff edges?

At patent expiry (or loss of a litigated patent), pyridone drugs usually follow one of two paths:

Outcome A: Fast erosion (low formulation/polymorph defense)

• Generic approvals convert quickly into substantial market share loss.
• Remaining differentiation comes from distribution contracts, brand switching friction, and payer protocols.

Outcome B: Delayed erosion via secondary patents

• Generic launches stall or move to a later date because the originator asserts formulation or solid-state patents.
• The “effective exclusivity” can shift by 1 to 4+ years depending on litigation pace and settlement timing.

Where do patent risks concentrate?

Patent risk in pyridone landscapes concentrates in three zones:

1) Solid-state claim vulnerability

Polymorph and solvate patents can be attacked on:

• Lack of novelty vs earlier literature or earlier filing disclosures
• Claim scope overbreadth or insufficient support
• Enablement challenges when the specification does not teach reliable reproducibility

2) Method-of-use claim sufficiency

Method patents face:

• Obviousness attacks tied to prior art dosing schedules and stratified populations
• “Not patentable subject matter” challenges are less common for typical method-of-use claims in this field, but claim drafting and post-2019 jurisprudence can matter.

3) Process patent enforceability

Process patents can become narrow if:

• Manufacturing evidence is hard to obtain
• Evidence focuses on manufacturing steps that differ between originator and generic

What does the enforcement geography imply for investors?

Pyridone drugs with:

• Strong EP family coverage and good national validation across major markets (DE, FR, UK, NL, IT, ES) can sustain parallel enforcement.
• A US-only stack can still preserve US revenue, but erosion in ex-US geographies can pressure consolidated valuation even if US remains protected.

Patent enforcement is also shaped by:

• Whether the solid-state forms are stable and reliably produced by generics
• Whether the originator controls key intermediates or manufacturing steps used in generic processes

How do patent term adjustments and regulatory timelines shift the timeline?

Even with identical filing dates, the practical exclusivity horizon changes due to:

• Patent term adjustments (PTA) at USPTO (for delays)
• Patent term extensions (PTE) tied to regulatory review (for certain products)
• Fast-track approvals or additional label expansions that trigger new coverage events

These timing levers affect:

• The expected time window for generic settlement strategy
• The amount of “runway” management uses to add label indications or line extensions before expiry

Market and patent landscape summary by practical investment logic

For originators or acquirers of a pyridone franchise

• Value protection tends to concentrate in solid-state IP and use IP, not just the primary compound.
• The most valuable portfolio units are the ones that sit in the Orange Book and are likely to remain enforceable through litigation.

For generic entrants and arbitrage investors

• The critical work is mapping Orange Book patents to the intended product and confirming whether:
  • Challenged patents are formulation, use, or process based
  • The generic can design around solid-state forms without losing bioequivalence
• Case-by-case outcomes dominate; the class name “pyridone” does not predict infringement.

Key Takeaways

• “Pyridone” is a scaffold label that spans distinct active ingredients; patent protection is therefore ingredient-specific, with repeatable structures: composition, solid-state product, method-of-use, and sometimes process.
• Market erosion at exclusivity cliffs is usually fast unless the originator has defensible secondary IP, especially polymorph/solvate and formulation patents that block ANDA launches or force design-arounds.
• In the US, Orange Book is the operational patent map for generic planning and therefore the primary dataset shaping the real-world timeline. [1]
• The investment outcome is driven less by the “pyridone” chemical label and more by whether the active ingredient has a durable patent stack aligned with regulatory approval and label scope. [1][2]

FAQs

1. Does the pyridone chemical class guarantee patent protection strength?
   No. Protection is ingredient-specific and depends on the compound’s patent family and the defensibility of secondary patents, especially solid-state/formulation.

2. What dataset matters most for US pyridone drug patent planning?
   The FDA Orange Book, because it lists patents associated with approved drug products and is used for ANDA challenge strategy. [1]

3. Why do polymorph and solvate patents matter in pyridone portfolios?
   They often provide the most practical late-stage infringement hooks for solid oral drugs and can delay generic entry when reliably reproduced forms are protected.

4. How do method-of-use patents affect generic competition for pyridone drugs?
   They can preserve label-specific exclusivity; generics may need carve-outs or face litigation if they attempt to market within covered indications or dosing regimens.

5. What ultimately determines the timing of generic erosion?
   The enforceability and litigation outcomes of Orange Book-listed patents and settlement dynamics under Hatch-Waxman, not the chemical scaffold alone. [1][2]

---

References

[1] U.S. Food and Drug Administration. (n.d.). Drugs@FDA and the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations). FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act). Public Law 98-417. https://www.congress.gov/ (see relevant bill text and summaries)